The Year of the Bildil?

Could it be that this year is the turnaround year for Nitromed(NTMD)? With their drug called Bildil which they are getting absolutely hammered on in sales, can they make a push for profitability? Their drug Bildil reduces heart failure by 43% in African Americans. I think with the replacements of the CEO and CFO, they are pumping their blood in the right direction. With NTMD looking to cut costs as a new strategy, I think this new executive staff will get the job done. Let me say this one more time, this is the year of the Bildil. Watch out for new strategic alliances with bigger drugmakers, to cut costs according to the conference call made by NTMD on Wednesday. If all else fails, Someone will pay a premium for this company who has a great product and works well with a soft heart. Currently: $8.22 Price Target: $14